Clinical Trial

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2025-05-23; most recent amendment 2026-06-01.
Status change: Not Yet Recruiting → Recruiting 2025-08-08
Trial Details
NCT Number NCT07002034
Lead Sponsor Reunion Neuroscience Inc
Conditions Adjustment Disorder
Enrollment 100 participants
Start Date 2025-07-30
Primary Completion 2026-11 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-06